Scholarlink

<p><i>Listeria monocytogenes</i> (Lm) is a facultative intracellular pathogen responsible for life-threatening listeriosis, characterized by high mortality rates. Currently, there is no vaccine available for the prevention or treatment of listeriosis. Here, we developed two adjuvanted inactivated vaccines and evaluated their safety, immunogenicity, and protective efficacy. The hypervirulent Lm strain XYSN was inactivated with β-propiolactone (BPL) and formulated with AddaVax or Alum to produce inactivated vaccines (ADIV and ALIV) respectively. Local reactogenicity and histopathological observations revealed no adverse reactions in a murine model. Humoral assays demonstrated both ADIV and ALIV induced higher antibody titers against Lm XYSN, with ADIV eliciting stronger cellular immune responses, as indicated by increased IL-17 and IFN-γ expression in spleen cells. Notably, ADIV conferred 83.3% protection against a lethal challenge with hypervirulent Lm strain, representing a 50% increase compared with the 33.3% protection achieved by ALIV. AddaVax adjuvant not only augmented humoral responses to inactivated bacterial cells but also elicited stronger cellular immune responses compared to Alum adjuvants, resulting in enhanced immune protection. This research offers insights into developing novel inactivated vaccines for listeriosis prevention, particularly beneficial for immunocompromised individuals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

AddaVax-Adjuvanted Inactivated Vaccine Confers Protection Against Listeria monocytogenes Challenge in Mice

  • 期刊论文

  • 发表日期：

    2026年2月11日

查看全文
  • Ye Wang,
  • Lisi Wu,
  • Chao Chen,
  • Fanzeng Meng,
  • Hongxiang Du,
  • Xiang Chen,
  • Xilong Kang,
  • Hao Yao,
  • Yuelan Yin,
  • Xin’an Jiao

摘要

Listeria monocytogenes (Lm) is a facultative intracellular pathogen responsible for life-threatening listeriosis, characterized by high mortality rates. Currently, there is no vaccine available for the prevention or treatment of listeriosis. Here, we developed two adjuvanted inactivated vaccines and evaluated their safety, immunogenicity, and protective efficacy. The hypervirulent Lm strain XYSN was inactivated with β-propiolactone (BPL) and formulated with AddaVax or Alum to produce inactivated vaccines (ADIV and ALIV) respectively. Local reactogenicity and histopathological observations revealed no adverse reactions in a murine model. Humoral assays demonstrated both ADIV and ALIV induced higher antibody titers against Lm XYSN, with ADIV eliciting stronger cellular immune responses, as indicated by increased IL-17 and IFN-γ expression in spleen cells. Notably, ADIV conferred 83.3% protection against a lethal challenge with hypervirulent Lm strain, representing a 50% increase compared with the 33.3% protection achieved by ALIV. AddaVax adjuvant not only augmented humoral responses to inactivated bacterial cells but also elicited stronger cellular immune responses compared to Alum adjuvants, resulting in enhanced immune protection. This research offers insights into developing novel inactivated vaccines for listeriosis prevention, particularly beneficial for immunocompromised individuals.